x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

SueWallSt

Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how the powerful play the game and sometimes get burned. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Go to ZLK.com for more on the case and follow us for the next corporate faceplant.

business investing

All Episodes

14:47

#133 $IT Strong Guidance or Silent Slowdown Inside...

SueWallSt ·

2026/04/03

Dive into the Gartner $IT controversy as we break down a securities class action tied to contract value growth, consulting revenue weakness, and alleged misleading guidance. This episode is for investors, traders, and anyone following tech services, enterprise demand, and market risk. Expect deep dives, real case analysis, and insights into slowing sales cycles, missed expectations, and sharp stock drops.Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

13:03

#132 $GO Growth Push or Costly Correction Inside...

SueWallSt ·

2026/04/02

Dive into the Grocery Outlet $GO controversy as we break down a securities class action tied to rapid store expansion, restructuring risks, and alleged misleading growth claims. This episode is for investors, traders, and anyone following retail stocks, expansion strategies, and market volatility. Expect deep dives, real case analysis, and insights into store closures, impairment charges, and stock drops.Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

17:09

#131 $ALIT Dividend Confidence or Collapse Inside...

SueWallSt ·

2026/04/02

Dive into the Alight $ALIT controversy as we break down a securities class action tied to execution failures, weak growth, and alleged misleading statements about margins and dividends. This episode is for investors, traders, and anyone following SaaS, HR tech, and market risk. Expect deep dives, real case analysis, and insights into leadership exits, guidance cuts, and stock crashes. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal

en

14:37

#130 $TCOM Antitrust Risk or Missed Warning Inside...

SueWallSt ·

2026/04/02

Dive into the Trip.com $TCOM controversy as we break down a securities class action tied to antitrust investigations, regulatory risk in China, and alleged misleading disclosures. This episode is for investors, traders, and anyone following tech platforms, global markets, and market volatility. Expect deep dives, real case analysis, and insights into regulatory scrutiny, risk disclosures, and stock drops. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

14:02

#129 $SLNO Breakthrough Drug or Hidden Risk Inside...

SueWallSt ·

2026/04/01

Dive into the Soleno Therapeutics $SLNO controversy as we break down a securities class action tied to drug safety, rare disease treatments, and alleged misleading statements around Vykat XR. This episode is for investors, traders, and anyone following biotech stocks, FDA approvals, and market risk. Expect deep dives, real case analysis, and insights into safety concerns, patient outcomes, and stock declines.Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

14:32

#128 $ODD Beauty Tech or Broken Ads Inside Oddity...

SueWallSt ·

2026/04/01

Dive into the Oddity Tech $ODD controversy as we break down a securities class action tied to digital advertising, customer acquisition costs, and algorithm driven disruptions. This episode is for investors, traders, and anyone following ecommerce, tech stocks, and market risk. Expect deep dives, real case analysis, and insights into ad auction dynamics, rising costs, and sudden stock drops.Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t take this

en

12:51

#127 $NKTR Trial Trouble When Clinical Confidence Cracks

SueWallSt ·

2026/04/01

Dive into the Nektar Therapeutics $NKTR controversy as we break down a securities class action tied to biotech trials, protocol violations, and alleged misleading statements around clinical execution. This episode is for investors, traders, and anyone following biotech stocks, drug development, and market risk. Expect deep dives, real case analysis, and insights into trial integrity, statistical outcomes, and stock reactions. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers

en

14:21

#126 $MNDY Growth Story or Slowing Momentum Inside...

SueWallSt ·

2026/03/31

Dive into the monday.com $MNDY controversy as we break down a securities class action tied to SaaS growth, enterprise sales trends, and shifting long term revenue targets. This episode is for investors, traders, and anyone following tech stocks, cloud platforms, and market volatility. Expect deep dives, real case analysis, and insights into slowing customer growth, longer sales cycles, and guidance cuts.Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

14:41

#125 $EOSE Battery Boom or Broken Ramp Inside Eos...

SueWallSt ·

2026/03/31

Dive into the Eos Energy $EOSE controversy as we break down a securities class action tied to battery technology, manufacturing automation, and missed revenue guidance. This episode is for investors, traders, and anyone following energy storage, clean tech, and market risk. Expect deep dives, real case analysis, and insights into production delays, downtime issues, and stock drops. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t take this as legal or

en

14:04

#124 $DRVN Restatement Shock When Financials Can’t Be...

SueWallSt ·

2026/03/31

Dive into the Driven Brands $DRVN controversy as we break down a securities class action tied to financial restatements, internal control failures, and accounting errors across multiple years. This episode is for investors, traders, and anyone following earnings quality, corporate governance, and market risk. Expect deep dives, real case analysis, and insights into unreliable financials, audit issues, and stock crashes. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or

en

12:24

#123 $CWH Inventory Control or Margin Collapse Inside...

SueWallSt ·

2026/03/30

Dive into the Camping World $CWH controversy as we break down a securities class action tied to inventory management, margin pressure, and alleged misleading statements about financial discipline. This episode is for investors, traders, and anyone following retail stocks, RV market trends, and market risk. Expect deep dives, real case analysis, and insights into inventory missteps, declining margins, and dividend cuts. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or

en

14:47

#122 $CHOW Pump Hype or Engineered Collapse Inside...

SueWallSt ·

2026/03/30

Dive into the ChowChow Cloud $CHOW controversy as we break down a securities class action tied to IPO activity, alleged stock manipulation, and social media driven trading schemes. This episode is for investors, traders, and anyone following micro cap stocks, IPO risks, and market volatility. Expect deep dives, real case analysis, and insights into pump and dump patterns, low float risks, and sudden stock crashes. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or

en

8:45

#121 $BSX Heart Growth Hype or Hidden Slowdown Inside...

SueWallSt ·

2026/03/30

Dive into the Boston Scientific $BSX controversy as we break down a securities class action tied to medical devices, electrophysiology growth, and alleged misleading statements around FARAPULSE adoption. This episode is for investors, traders, and anyone following healthcare stocks, medtech innovation, and market risk. Expect deep dives, real case analysis, and insights into competition, slowing procedure volumes, and stock drops. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not

en

8:29

#120 $AQST FDA Delay Shock The Allergy Drug Setback...

SueWallSt ·

2026/03/29

Dive into the Aquestive Therapeutics $AQST controversy as we break down a securities class action tied to biotech approvals, FDA delays, and alleged misleading timelines around Anaphylm. This episode is for investors, traders, and anyone following biotech stocks, drug approvals, and market volatility. Expect deep dives, real case analysis, and insights into regulatory risk, clinical setbacks, and stock drops. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

9:19

#119 $APO Wall Street Secrets The Apollo Epstein...

SueWallSt ·

2026/03/29

Dive into the Apollo Global Management $APO controversy as we break down a securities class action tied to alleged undisclosed ties, reputational risk, and investor disclosures. This episode is for investors, traders, and anyone following hedge funds, Wall Street news, and market transparency. Expect deep dives, real case analysis, and insights into corporate governance, disclosure risks, and stock reactions. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

8:35

#118 $SNOW Cloud Growth or Hidden Headwinds Inside...

SueWallSt ·

2026/03/29

Dive into the Snowflake $SNOW controversy as we break down a securities class action tied to cloud computing, consumption based revenue, and unexpected growth headwinds. This episode is for investors, traders, and anyone following tech stocks, data platforms, and market volatility. Expect deep dives, real case analysis, and insights into pricing models, efficiency impacts, and stock drops. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t take this as

en

8:56

#117 $NAVN IPO Turbulence What Investors Weren’t Told

SueWallSt ·

2026/03/28

Dive into the Navan $NAVN controversy as we break down a securities class action tied to IPO disclosures, rising sales and marketing costs, and post IPO stock declines. This episode is for investors, traders, and anyone following tech stocks, IPOs, and market risk. Expect deep dives, real case analysis, and insights into financial transparency, growth metrics, and investor expectations. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t take this as

en

9:19

#116 $LAKE Growth Strategy or Cracks in the...

SueWallSt ·

2026/03/28

Dive into the Lakeland Industries $LAKE controversy as we break down a securities class action tied to acquisitions, operational challenges, and missed financial guidance. This episode is for investors, traders, and anyone following industrial stocks, M and A strategies, and market risk. Expect deep dives, real case analysis, and insights into earnings misses, supply chain issues, and stock declines. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so

en

9:00

#115 $FBRT Dividend Cut Shock Income Investors...

SueWallSt ·

2026/03/28

Dive into the Franklin BSP Realty Trust $FBRT controversy as we break down a securities class action tied to REIT dividends, commercial real estate debt, and alleged misleading statements about earnings power. This episode is for income investors, traders, and anyone following dividend stocks, REITs, and market risk. Expect deep dives, case analysis, and insights into dividend cuts, earnings pressure, and investor expectations. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers

en

8:19

#114 $CORT FDA Shock The Approval That Never Came

SueWallSt ·

2026/03/27

Dive into the Corcept Therapeutics $CORT controversy as we break down a securities class action tied to biotech approvals, FDA setbacks, and alleged misleading statements حول relacorilant. This episode is for investors, traders, and anyone following biotech stocks, clinical trials, and market volatility. Expect deep dives, case analysis, and insights into FDA risk, insider selling, and stock crashes. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t

en

133 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...